Eclipsys Announces Highlights for 2009 Annual User Conference

Eclipsys Corporation^® (NASDAQ:ECLP), The Outcomes Company^®, today announced upcoming highlights for its 2009 Eclipsys User Network (EUN) Outcomes Conference, October 14-17 in Dallas, TX. The EUN conference creates an annual forum of thousands of Eclipsys user representatives from world-renown healthcare systems, including 40 percent of "America’s Best Hospitals,” according to the U.S. News & World Report’s 2009 ranking. The elite community of Eclipsys users also represents 45 percent of all organizations accepted into the Magnet Recognition Program®, which recognizes health care organizations that provide nursing excellence.

New this year to EUN is an executive leadership agenda to provide details of Eclipsys’ American Reinvestment and Recovery Act (ARRA) programs, including special available financing, the company’s ARRA-HITECH warranty and a preview of the Sunrise Enterprise™ 5.5 solution, slated as Eclipsys’ ARRA 2011 Certified EHR (electronic health record) Technology.

With more than 160 sessions scheduled over the course of four days, this year’s EUN also will feature new Oncology, Pediatrics, and Academic specialty tracks, reflecting the fact that Eclipsys offers some of the most advanced computerized physician order entry (CPOE) functionality in the market, including support for complicated treatment plans commonplace in oncology and pediatric care environments. Eclipsys was cited in the KLAS CPOE Digest 2009: Meaningful Use and Physician Adoption report (KLAS CPOE Digest 2009) issued by KLAS Enterprises, Inc. (KLAS), as having invested more time and effort in building an oncology extension into its clinical information system than other companies due to its physician adoption formula.

Other key highlights at the 2009 Eclipsys EUN Outcomes Conference include:

• A company update from Eclipsys President and CEO, Phil Pead;
• An overview of the freely available Eclipsys Outcomes Toolkits, which support Eclipsys client collaboration and sharing of best practices for care, including the company’s HINI Toolkit developed in April 2009;
• Physician practice sessions focused on the company’s PeakPractice™ Ambulatory EHR solution.

Superiority in CPOE Positions Eclipsys Clients Well for ARRA "Meaningful Use” Requirements

"Eclipsys users are an elite group of healthcare providers that benefit from our company’s 30 years of unmatched, continuous evolution in CPOE capabilities, and as such, we believe our clients perform at a higher level in terms of quality and outcomes,” said Jay Deady, Eclipsys’ executive vice president of Client Solutions. "In fact, based on publicly available data from the U.S. Department of Health and Human Services Hospital Compare site, Eclipsys clients rank No. 1 in composite performance across all Centers for Medicare and Medicaid Services Quality Measures. That data reinforces our client community’s increased ability to affect positive patient outcomes and offer a safer clinical environment. As ARRA ‘meaningful use’ requirements are expected to become more advanced in 2013 and 2015, we believe our clinical solution’s open architecture and highly complex clinical decision support capabilities will continue to bring even more value to Eclipsys clients and the patients they serve.”

The Eclipsys EHR solution, Sunrise Clinical Manger™, has garnered widespread clinician adoption and has been recognized by KLAS as one of the industry’s leading electronic records solutions. The system’s capabilities are expected to advance a healthcare enterprise to "meaningful use” status in time to comply with ARRA requirements. Integrated with a comprehensive offering of enterprise applications, the solution maximizes electronic health record benefits by offering interoperable, fully connected care. According to the KLAS CPOE Digest 2009 report, Eclipsys CPOE solutions are used by more physicians in more hospitals than any other vendor systems. The company also continues to have the highest physician satisfaction from clients who use its system, and on average, highly customizable ordering capabilities allow a physician to order faster than any other CPOE solution on the market.

About the Magnet Recognition Program

The Magnet Recognition Program® was developed by the American Nurses Credentialing Center (ANNC) to recognize healthcare organizations that provide nursing excellence. The program also provides a vehicle for disseminating successful nursing practices and strategies. Recognizing quality patient care, nursing excellence and innovations in professional nursing practice, the Magnet Recognition Program provides consumers with the ultimate benchmark to measure the quality of care that they can expect to receive. For more information, go to www.nursingcredentialing.com.

About the KLAS CPOE Digest 2009

The KLAS CPOE Digest 2009 compiled data from healthcare executives, managers and clinicians. The study provided detailed information on several criteria including current CPOE usage at healthcare organizations, product capabilities and vendor performance.

About the Hospital Compare Web site

Hospital Compare was created through the efforts of the Centers for Medicare & Medicaid Services (CMS), the U.S. Department of Health and Human Services, and other members of the Hospital Quality Alliance: Improving Care Through Information (HQA). The information on this website comes from hospitals that have agreed to submit quality information for Hospital Compare to make public. For more information, go to www.hospitalcompare.hhs.gov.

About KLAS

KLAS is a research firm specializing in monitoring and reporting the performance of healthcare vendors. KLAS' mission is to improve delivery, by independently measuring vendor performance for the benefit of our healthcare provider partners, consultants, investors, and vendors. Working together with executives from over 4500 hospitals and over 2500 clinics, KLAS delivers timely reports, trends, and statistics, which provide a solid overview of vendor performance in the industry. KLAS measures performance of software, professional services, and medical equipment vendors. For more information, go to www.KLASresearch.com , or email marketing@KLASresearch.com , or call 1-800-920-4109 to speak with a KLAS representative.

About Eclipsys

Eclipsys is a leading provider of advanced integrated clinical, revenue cycle and performance management software, clinical content and professional services that help healthcare organizations improve clinical, financial and operational outcomes. For more information, see www.eclipsys.com or email info@eclipsys.com.

Statements in this news release concerning the timing of implementation and features of and benefits provided by Eclipsys software and implementation services are forward-looking statements and actual results may differ from those projected due to a variety of risks and uncertainties. Implementation and customization of Eclipsys software is complex and time-consuming. Results depend upon a variety of factors and can vary by client. Each client’s circumstances are unique and may include unforeseen issues that make it more difficult than anticipated to implement or derive benefit from Eclipsys software or services. The success and timeliness of the company’s services will depend at least in part upon client involvement, which can be difficult to control. Eclipsys is required to meet specified performance standards, and the contract can be terminated or its scope reduced under certain circumstances. More information about company risks is available in recent Form 10-Q and 10-K filings made by Eclipsys from time to time with the Securities and Exchange Commission. Special attention is directed to the portions of those documents entitled "Risk Factors” and "Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Eclipsys Corporation and The Outcomes Company are registered trademarks of Eclipsys Corporation. Sunrise Enterprise, PeakPractice and Sunrise Clinical Manager are trademarks of Eclipsys Corporation. Other product and company names in this news release are trademarks and/or registered trademarks of their respective companies.